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Abstract
Background: Despite evidence linking obesity to impaired immune function, little is known about the specific
mechanisms. Because of emerging evidence that immune responses are epigenetically regulated, we hypothesized
that DNA methylation changes are involved in obesity induced immune dysfunction and aimed to identify these
changes.
Method: We conducted a genome wide methylation analysis on seven obese cases and seven lean controls aged
14 to 18 years from extreme ends of the obesity distribution and performed further validation of six CpG sites from
six genes in 46 obese cases and 46 lean controls aged 14 to 30 years.
Results: In comparison with the lean controls, we observed one CpG site in the UBASH3A gene showing higher
methylation levels and one CpG site in the TRIM3 gene showing lower methylation levels in the obese cases in
both the genome wide step (P = 5 × 10-6 and P = 2 × 10-5 for the UBASH3A and the TRIM3 gene respectively)
and the validation step (P = 0.008 and P = 0.001 for the UBASH3A and the TRIM3 gene respectively).
Conclusions: Our results provide evidence that obesity is associated with methylation changes in blood leukocyte
DNA. Further studies are warranted to determine the causal direction of this relationship as well as whether such
methylation changes can lead to immune dysfunction.
See commentary: http://www.biomedcentral.com/1741-7015/8/88/abstract
Background
Obesity is the epidemic of our time, with sharply and
steadily rising rates [1,2]. The major adverse conse-
quences of obesity including type 2 diabetes, athero-
sclerosis and essential hypertension, when added
together, account for a large number of disease related
deaths [3,4]. If the obesity-related cancer cases are
added to this number, obesity-related mortality by far
exceeds that of other common diseases [5]. The latter
indicates the urgent need to develop novel efficient ther-
apeutic modalities for this condition.
The common denominator in the pathogenesis of the
co-morbidities of obesity is the presence of an active,
low-grade inflammatory process [6]. Despite evidence
linking obesity to alterations in inflammatory response,
little is known about the specific effects of obesity on
the immune system. Recently, there has been a greater
appreciation of the role of epigenetics, meiotically and
mitotically heritable changes in gene expression that are
not coded in the DNA sequence itself, in the immune
and inflammatory responses [7-9]. Therefore, we
hypothesize that DNA methylation changes play a role
in obesity induced immune dysfunction. The goal of this
study was to characterize DNA methylation profile in
peripheral blood leukocytes in obese versus lean subjects
using a genome wide approach. Identification of methy-
lation changes in specific genes will provide important
targets for further study into the mechanisms of obe-
sity’s effect on the immune system and the potential to




The genome wide methylation analysis was conducted
in seven obese and seven age-matched lean controls.
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These 14 subjects were identified from the participants
(n = 534) in the Lifestyle, Adiposity, and Cardiovascular
Health in Youth (LACHY) study using the following
inclusion criteria: (1) African American (AA) ancestry;
(2) male; (3) having leukocyte DNA available; (4) obese
cases having a body mass index (BMI) ≥ 99th percentile
for age and sex and lean controls having BMI ≤ 10th
percentile for age and sex. The LACHY study consisted
of roughly equal numbers of AA and European Ameri-
can (EA) adolescents aged 14 to 18 years of both sexes
recruited from high schools in the Augusta, Georgia
area [10].
The replication cohort included 46 obese (BMI ≥ 30
kg/m2 or BMI ≥ 95th percentile for age and sex if age ≤
18) and 46 lean (BMI ≤ 22 kg/m2 or BMI ≤ 40th percentile
for age and sex if age ≤ 18) AA males selected from three
cohorts, the Blood Pressure (BP) stress study (n = 603)
[11], the Georgia Cardiovascular twin study (n = 1,183)
[12] and the Prevention of Hypertension in African Amer-
ican Teens (PHAT) study (n = 262) [13]. Both the BP
Stress study and the twin study are on-going longitudinal
studies which have followed the subjects more than 10
years. Both studies included roughly equal numbers of
AAs and EAs or males and females. The BP stress study
was established in 1989 with subjects aged to 7 to 16 years
at baseline and the twin study was established in 1996
with subjects aged 7 to 25 years at baseline [11,12]. The
PHAT study was a cross-sectional study and consisted of
AA males and females aged 14 to 20 years [13]. Subjects
in all the three studies were also recruited from Augusta,
GA area. The obese and lean subjects were identified
based on the following criteria: (1) having leukocyte DNA
available; (2) AA males; (3) only one twin subject from a
twin pair was selected if both twins met the criteria; (4) if
multiple visits (with multiple leukocyte DNA) were avail-
able for a subject, this subject had to be obese or lean on
all the visits to be included in the replication sample and
the leukocyte DNA collected at the visit when the subject
were the most obese or most lean was used.
For all four cohorts self identification by self-reports of
each subject or by a parent if the subject was under
18 years of age was used to classify ethnicity according to
previously described criteria [14]. Subjects in all the four
studies were overtly healthy, free of any acute or chronic ill-
ness on the basis of parental reports and were not on anti-
hypertensive, lipid lowering, anti-diabetic and anti-inflam-
matory medications [10-13]. The Institutional Review
Board at the Medical College of Georgia approved the stu-
dies. Informed consent was obtained from all subjects and
by parents if subjects were less than 18 years of age.
Measurements
For all the four cohorts, height and weight were mea-
sured by standard methods using a wall-mounted
stadiometer and a scale, respectively. BMI was calculated
as weight/height2. Systolic BP (SBP) and diastolic BP
(DBP) were measured with Dinamap monitors, using an
appropriately sized BP cuff placed on the subject’s right
arm. BP measurements were taken at 11, 13, and 15
minutes, during a 15-minute supine relaxation period.
The average of the last two readings was used to repre-
sent SBP and DBP values [10-13].
Fasting peripheral blood samples in the LACHY
cohort and non-fasting peripheral blood samples in the
other three cohorts were collected. The buffy coat and
plasma samples were separated and stored at -80°C.
DNA was extracted from the buffy coat. In the LACHY
cohort, fasting glucose levels were measured using Ekta-
chem DT II system (Johnson and Johnson Clinical Diag-
nostics, Rochester, NY, USA) and fasting insulin was
assayed in duplicate by specific radioimmunoassay
(Linco Research, Inc., St Charles, MO, USA) [10].
QUICKI (quantitative insulin-sensitivity check index)
was calculated to index insulin sensitivity using the fol-
lowing formula: 1/[log(fasting insulin, μU/ml) + log(fast-
ing glucose, mg/dl)]. Out of the screening sample which
included the seven obese cases and seven lean controls
selected from the LACHY cohort, fasting glucose and
insulin levels were not available for one case and one
control.
Genome wide methylation chip
The HumanMethylation27 BeadChip from Illumina
(Illumina, San Diego, CA, USA) was used. This chip
can quantitatively measure 27,000 CpG sites, covering
more than 14,000 well-annotated genes at single-CpG
resolution. Each chip can accommodate 12 samples.
After bisulfite treatment, 200 ng of the converted
DNA was whole genome amplified (WGA) and enzy-
matically fragmented. The bisulfite-converted
WGA-DNA samples were purified and applied to the
BeadChips. Image processing and intensity data
extraction were performed according to Illumina’s
instruction http://www.illumina.com/products/infi-
nium_humanmethylation27_beadchip_kits.ilmn. Each
methylation data point is represented by fluorescent
signals from the methylated and unmethylated alleles.
DNA methylation beta values are continuous variables
between 0 (completely unmethylated) and 1 (comple-
tely methylated), representing the ratio of the inten-
sity of the methylated bead type to the combined
locus intensity. Initial array processing and quality
control were performed with BeadStudio software.
The microarray data discussed in this paper have
been deposited in NCBI’s Gene Expression Omnibus
and are accessible through GEO Series accession
number GSE25301 http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE25301.
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Pyrosequencing
The methylation levels of the selected six CpG sites
from the six genes in the replication cohort were deter-
mined by pyrosequencing technology, a rapid and robust
method for quantitative methylation analysis. After
bisulfite treatment, 10 ng of the converted DNA was
used in a PCR reaction to amplify the target region.
One of the PCR primers was biotin labeled. Single-
stranded biotinylated PCR products were prepared for
sequencing by use of the Pyrosequencing Vacuum Prep
Tool according to the manufacturer’s instructions. The
PCR products (each 10 μl) were sequenced by Pyrose-
quencing PSQ96 HS System (Pyrosequencing-Qiagen)
following the manufacturer’s instructions. The methyla-
tion status of each locus was analyzed individually as a
T/C SNP using QCpG software (Biotage, Kungsgatan,
Sweden). PCR primers and sequencing primers for these
six genes are listed in Additional file 1. All the samples
were assayed in the same run and in a random
sequence.
Statistical analysis
For the genome wide methylation analysis, the Limma
package [15] was used to analyze each CpG site for dif-
ferential methylation between obese and lean subjects.
CpG sites on the × and Y chromosomes were excluded
from the analysis. Each CpG site was assigned a raw P-
value based on a moderated t statistic. To correct for
multiple testing, the set of raw P-values were converted
to false discovery rates (FDR) according to Benjamini
and Hochberg [16]. For the six CpG sites in the replica-
tion cohort, a Student’s t-test was used to investigate
whether their methylation levels differ between the
obese and the lean group. Linear regression was further
used to adjust the potential effect of age on methylation
levels. We combined the genome wide and the replica-
tion steps for these six CpG sites using the weighted z
score-based meta-analysis approach implemented in the
package METAL [17]. Prior to analysis, methylation
levels of the CpG sites in the replication cohort were
log-transformed or square root-transformed to obtain a
better approximation of the normal distribution. Preli-
minary analyses, t-tests and regression analyses were
done using STATA 8 (StataCorp, College Station, TX,
USA).
Gene Ontology analysis was conducted with the
FatiGO tool [18]. FatiGO takes two lists of genes and
converts them into two lists of GO terms. Then a Fisher’s
exact test for 2 × 2 contingency tables is used to check
for significant over-representation of GO terms in one of
the sets with respect to the other one. Multiple testing
correction (indexed by adjusted P-values) to account for
the multiple hypothesis tested (one for each GO term) is
applied to reduce false positives. Since at least two CpG
sites were included for the majority of genes in this gen-
ome wide chip, we selected the CpG sites with the lowest
p value to represent this gene.
Results
Table 1 displays the general characteristics of the
screening sample. At this age range, obese subjects
already showed significantly higher insulin resistance.
Figure 1 is a volcano plot showing the raw P-values for
all CpG sites versus mean methylation difference
between the obese group and the lean group. We did
not observe any CpG sites survive multiple testing cor-
rection with the most significant CpG site with a FDR
of 0.14 and a raw P-value of 5 × 10-6. Table 2 lists the
top 10 most significant CpG sites and one additional
CpG site which showed the largest methylation differ-
ence between cases and controls (-27.1% for CREB3L3).
Since at least two CpG sites were included for the
majority of the genes in this genome wide methylation
chip, the P-value for the second CpG site in this gene
was also listed in Table 2. Out of the 11 CpG sites listed
in Table 2 (under the column “more significant CpG
site”), we selected six CpG sites for validation in the
replication cohort using the following inclusion criteria:
(1) the most significant differentially methylated CpG
site, which is the CpG site locating at -156 of the UBA-
SH3A (ubiquitin-associated and SH3 domain-containing
protein A) gene; or (2) the CpG sites in those genes of
which the second CpG site also showed a raw P < 0.05.
These include the CpG sites from the TRIM3 (Tripartite
motif-containing 3), CTSZ (Cathepsin Z preproprotein),
HIPK3 (Homeodomain interacting protein kinase 3),
CDH5 (Cadherin 5 type 2 preproprotein) and CREB3L3
(cAMP responsive element binding protein 3-like 3)
genes. The validation was conducted on the more signif-
icant CpG site (with Illumina ID 13517, 17029, 23241,
25599, 8829 and 23739) in each gene by pyrosequen-
cing. The general characteristics of the replication
cohort are displayed in Table 3. Since the DNA from
one obese subject failed on four pyrosequencing assays,
the data from this subject was excluded from the analy-
sis. Table 4 lists the results in the replication cohort.
The findings from the genome wide methylation chip
were validated for the CpG sites in the UBASH3A,
TRIM3, HIPK3 and CDH5 genes. The methylation sta-
tus of the CpG site in the UBASH3A gene was 3.3%
higher (P = 0.0019) and the methylation status of the
CpG site in the TRIM3, HIPK3 and CDH5 genes was
1.21% (P = 0.0004), 7.31% (P = 0.0135) and 3.09% (P =
0.045) lower in the obese versus the lean group. These
significant findings persisted after adjustment of age for
the association between obesity and methylation status
of the CpG site in the UBASH3A gene (P = 0.008) and
TRIM3 gene (P = 0.001), but changed to borderline
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significance for HIPK3 gene (P = 0.05), and disappeared
for the CpG site in the CDH5 gene (P = 0.095). The
results of the meta-analysis for these six CpG sites on
the data from the genome wide step and the replication
step are shown in Additional file 2
Although the pyrosequencing assay was designed to
target one specific CpG site for each gene, some of the
assays covered several surrounding CpG sites. The results
of these CpG sites are also listed in Table 4. The correla-
tion within samples among the multiple CpG sites mea-
sured within a gene is listed in Additional file 3.
Gene Ontology analysis was performed to test whether
some common functional trends in molecular functions
and biological processes were associated with the genes
exhibiting differences between obese cases and lean con-
trols in the genome wide chip. We included those genes
with a raw P ≤ 0.01 to the first list (n = 298) and included
all the other genes in the second list. As expected from a
pilot study in 14 subjects, we did not observe any GO
categories survive multiple testing. Table 5 lists the GO
categories with raw P-value less than 0.05. Interestingly,
we observed enriched functional processes that are
potentially relevant for inflammatory response with
immune response (GO:0006955), cell activation
(GO:0001775), cytokine production (GO:0001816),
response to biotic stimulus (GO:0009607) and antigen
binding (GO:0003823) among the top GO categories.
The results support that obesity might lead to methyla-
tion changes in genes involved in inflammatory pathways.
Discussion
In this study we aimed to identify obesity related methy-
lation changes in peripheral blood leukocytes using a
genome wide approach in youth and young adults who
are free of obesity comorbidities. The primary findings
of this study are increased methylation levels at one
CpG site in the UBASH3A gene and decreased methyla-
tion level at one CpG site in TRIM3 gene in obese sub-
jects compared with lean controls.
The protein encoded by the UBASH3A gene is the
“ubiquitin-associated and SH3 domain-containing pro-
tein A”, which was previously also known as T-cell ubi-
quitin ligand (TULA) and suppressor of T-cell signaling
2 (Sts-2). It is expressed predominantly in T-cells, where
it has a suppressing effect on T-cell signaling and activa-
tion. It acts in part by inhibiting c-CBL-mediated down-
regulation of protein tyrosine kinases (PTKs) that are
activated upon T-cell receptor stimulation [19]. UBA-
SH3A is also capable of promoting T-cell apoptosis [20].
UBASH3A and UBASH3B (another protein in this
family) gene double knock-out mice were hyperrespon-
sive to T-cell receptor stimulation with increased cyto-
kine secretion, although mice lacking UBASH3A were
normal in all respects including T-cell function [21].
However, whether the expression of the UBASH3A gene
is regulated by DNA methylation is unknown. No CpG
island exists in this gene and the CpG site showing
higher methylation levels in obese subjects from this
Table 1 General characteristics of the subjects for genome wide methylation analysis
Cases Controls
N 7 7
Age, years 15.8 ± 1.0 (14.5 to 17.2) 15.9 ± 1.4 (15.1 to 18.1)
*BMI, kg/m2 39.0 ± 1.7 (37.2 to 41.2) 17.0 ± 0.7 (16.4 to 17.8)
*BMI percentile 0.996 ± 0.001 (0.995 to 0.997) 0.048 ± 0.022 (0.026 to 0.091)
SBP, mmHg 125.8 ± 13.9 (115.3 to 152.7) 112.7 ± 8.9 (100.7 to 124.7)
†‡Fasting insulin, uU/ml 35.9 ± 13.6 (19.8 to 58.9) 13.7 ± 3.0 (9.4 to 17.0)
‡Fasting glucose, mg/dl 103.5 ± 14.8 (84 to 126) 88.8 ± 7.6 (80 to 100)
*‡QUICKI 0.28 ± 0.01 (0.27 to 0.30) 0.33 ± 0.01 (0.31 to 0.35)
Means ± SD (Range)
*: P < 0.001; †: P < 0.01
‡: Available for six cases and six controls
Figure 1 Volcano plot showing raw P-values versus mean
methylation difference between obese cases and lean controls.
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study locates at the promoter region with a distance of
156 bp to the transcription start site. There is a possibi-
lity that methylation of this CpG site or other CpG sites
with methylation levels correlated with this CpG site
inhibits the interactions between DNA sequence and
nuclear proteins, resulting in decreased gene expression.
In-silico analysis of the region of this CpG site using
TFSEARCH software [22] did not find this CpG site
located at any known transcription factor binding sites.
However, methylation of this CpG site may suppress
gene transcription by recruiting methylcytosine-binding
proteins that in turn associate with large protein com-
plexes containing corepressors and histone deacetylases.
The binding of these complexes to DNA may lead to a
change in the chromatin structure from an active to an
inactive form [23]. This speculation needs to be
confirmed.
TRIM3 is one member of the TRIM protein family.
These proteins share a conserved tripartite architecture
and have a variety of cellular functions including cell
proliferation, differentiation, oncogenesis, apoptosis,
immune signaling and have been implicated in autoim-
mune diseases [24]. In peripheral blood leukocytes,
TRIM3 is mainly expressed in macrophages and can be
up-regulated by viral infection [25,26]. Similar to
UBASH3A, the role of methylation in TRIM3 gene
expression has not been reported yet. The TRIM3 gene
has 1 CpG island located in the promoter and exon 1
(nucleotides -446 to 576), one CpG island spanning
intron 2 and exon 3 (nucleotides 7759 to 8334), and one
CpG island in exon 13 and the downstream region
(nucleotides 24883 to 25610). The CpG site showing
lower methylation levels in obese subjects in both the
scanning cohort and the replication cohort locates in
the promoter CpG island (348 bp upstream to the tran-
scription start site). The methylation status of the other
CpG site which showed significant differential methyla-
tion levels between obese cases and lean controls in the
genome wide methylation analysis also locates in this
CpG island (331 bp upstream to the transcription start
site). Because the pyrosequencing assay also measured
the methylation levels of the -331 CpG site (Illumina
ID: 19207), we were able to show that also for this site
obese subjects had lower methylation levels in compari-
sons with the lean subjects (age adjusted P = 0.022 as
shown in Table 4). Similar to the CpG site in the UBA-
SH3A gene, these two CpG sites are not located at any
known transcription factor binding sites. Future studies
will be needed to test whether the density of the methy-
lation or the methylation of specific CpG sites in this
CpG island has effect on TRIM3 gene expression.
The observed DNA methylation differences between
obese cases and controls were relatively small. They
were 10.1% and 2.54% in the genome wide step and
3.3% and 1.2% in the replication step for the UBASH3A
gene and the TRIM3 gene, respectively. This modest
level of differences raises an important question: what is
the biological significance of changes in methylation on
this degree? In this study, we used the DNA from leuko-
cytes, which represent different cell populations with
Table 2 Top 10 differentially methylated CpG sites and the CpG site showing the largest difference.
Gene More significant CpG site Second CpG site
ID Dis. to TSS Average
Case/Con. (%)





UBASH3A 13517 -156 45.6/35.5 10.1 5.00 × 10-6 0.14 146 52 45.6/37.7 7.9 0.145
CTNND1 6160 -431 57.4/70.2 -12.8 2.00 × 10-5 0.20 18016 415 19.7/21.5 -1.8 0.353
TRIM3 17029 -348 6.74/9.28 -2.54 2.40 × 10-5 0.20 19207 -331 12.5/16.2 -3.7 0.035
CTSZ* 23241 -292 13.6/21.0 -7.40 4.40 × 10-5 0.24 1644 -592 17.4/25.6 -8.2 0.001
TRAF5 10097 -319 69.7/58.0 11.7 4.50 × 10-5 0.24 25786 77 1.90/1.79 0.1 0.738
HIPK3 25599 390 51.5/64.9 -13.4 6.50 × 10-5 0.26 5514 314 26.6/35.0 -8.4 0.006
DPCR1 20918 -46 62.5/70.2 -7.70 6.90 × 10-5 0.26 4703 -906 72.4/73.0 -0.6 0.709
HIF3A 2879 153 5.35/2.97 2.38 1.08 × 10-4 0.34 7009 -1445 57.1/63.0 -5.9 0.091
NOTCH4 5969 -51 59.1/68.5 -9.40 1.15 × 10-4 0.34 14700 4 19.3/23.6 -4.3 0.078
CDH5 8829 -243 27.2/36.5 -9.20 1.75 × 10-4 0.44 22286 36 72.5/81.3 -8.8 0.012
CREB3L3 23739 42 9.63/36.7 -27.1 1.78 × 10-3 0.59 13445 -26 5.74/25.8 -20.1 0.004
Genes taken forward to the replication stage are shown in bold.
ID: ID from Illumina HumanMethylation27 BeadChip; Dis. to TSS: Distance to the Transcription Start Site; FDR: False Discover Rate
* For CTSZ, 7 CpG sites were included in the genome-wide methylation platform and the two most significant sites are listed in the table.




*Age, years 20.3 ± 5.0 (14.1 to 29.5) 17.6 ± 3.1 (12.7 to 27.9)
†BMI, kg/m2 37.4 ± 6.1 (30.5 to 59.9) 18.9 ± 1.2 (16.4 to 22.0)
†SBP, mmHg 125.8 ± 14.2 (97 to 175) 113.5 ± 8.5 (100 to 134)
Means ± SD (Range)
*: P < 0.01; †: P < 0.001
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distinct epigenetic profiles. It is plausible that only the
change in the epigenetic profile of one specific cell type
is related to obesity. In this regard, the actual epigenetic
differences might be more substantial than reported
here but only present in this specific blood leukocyte
cell type. Future studies on epigenetic profiling of var-
ious types of cell populations in the leukocytes are war-
ranted to gain a greater understanding of the epigenetic
dysregulation in obesity. Furthermore, this kind of study
will be able to identify the cells specifically reflecting
obesity-associated methylation changes, which is of
great interest in itself. Transcriptional profiling studies
will be very valuable in understanding whether the DNA
methylation status differences are associated with differ-
ences in gene expression. Unfortunately, cellular RNA is
not available for the samples used in the current study,
which were selected from several existing cohorts.
There are several strengths of this study. First, we
selected obese cases and controls with extreme pheno-
types, which maximizes the power to make discoveries.
Second, we focused on youth and young adults with the
distinct advantage that the results are not confounded
by obesity comorbidities or use of medication, both of
which are very common in adult subjects with obesity.
Third, a hypothesis-free genome wide approach was
used. This approach supersedes the limitations imposed
by candidate gene methylation studies and allows
searching the whole genome in an unbiased manner.
Interpretation of these data is also limited by several
constraints. First, in this study we hypothesize that obesity
will lead to methylation changes in the DNA of leukocytes,
which further lead to obesity related co-morbidities. How-
ever, our study design cannot determine whether the iden-
tified methylation changes are the cause or the
consequence of obesity. Future studies on subjects who
changed their body size status will be needed to clarify the
causal directions. On the other hand, epigenetic regulation
is tissue specific. In this regard, the target tissue to identify
epigenetic variations responsible for obesity should be the
hypothalamus of the brain rather than peripheral leuko-
cytes. Second, in the current study, the Infinium Human-
Methylation27 Beadchip was selected because of its
quantitative measure at each CpG site. However, the lim-
ited coverage of this genome wide chip will restrict the
findings to certain CpG sites within certain genes. Future
studies should use chips with more complete coverage of
the genome such as the recently released 450K Infinium
Methylation BeadChip from Illumina. Third, the current
study is a small pilot study with the genome wide step
conducted only in seven obese and seven lean subjects.
Table 4 Results from the replication cohort
Gene ID Dis. to TSS Average
Case/Con. (%)
Difference (%) P Age adjusted
P
UBASH3A 13517 -156 45.1/41.8 3.30 0.0019 0.008
TRIM3 — -357 8.58/8.98 -0.40 0.3128 0.059
17029 -348 8.76/9.97 -1.21 0.0004 0.001
19207 -331 6.91/7.93 -1.02 0.0050 0.022
CTSZ 23241 -292 16.5/17.7 -1.20 0.0953 0.271
— -279 27.8/29.1 -1.30 0.8425 0.798
HIPK3 — 375 48.0/55.3 -7.30 0.0184 0.061
25599 390 49.8/57.1 -7.30 0.0135 0.050
— 422 39.8/45.8 -6.00 0.0164 0.070
— 438 42.5/49.0 -6.50 0.0173 0.061
CDH5 8829 -243 30.3/33.4 -3.10 0.0450 0.092
CREB3L3 — 30 3.23/2.85 0.38 0.7188 0.828
23739 42 18.7/21.6 -2.90 0.3251 0.288
— 48 18.5/22.3 -3.80 0.1549 0.174
ID, ID from Illumina HumanMethylation27 BeadChip
Dis. to TSS, Distance to the Transcription Start Site.
The targeted CpG sites are highlighted in bold.
Table 5 Gene-ontology Analysis
Biological
process




Level 3 GO:0006955 Immune response 0.017 0.690
Level 3 GO:0007588 Excretion 0.028 0.690
Level 3 GO:0001775 Cell activation 0.042 0.690
Level 3 GO:0001816 Cytokine production 0.044 0.690









Level 3 GO:0019842 Vitamin binding 0.009 0.522
Level 3 GO:0003823 Antigen binding 0.010 0.522
Level 3 GO:0004872 Receptor activity 0.032 0.756
Level 3 GO:0008289 Lipid binding 0.035 0.756
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Future studies with much larger sample size are war-
ranted to discover a more complete profile of obesity
related methylation changes. Fourth, although all the
obese cases in the genome-wide step were free of clinical
diseases such as CVD and diabetes, some of them already
showed evidence of insulin resistance. It is possible that
insulin resistance may be the factor triggering methyla-
tion changes and not the obesity per se. Recent literature
supports the postulate that glucose restriction alters gene
expression through epigenetic mechanisms [27]. We con-
ducted further analysis within the obese cases and did
not observe that any of the CpGs showed methylation
difference between cases with impaired fasting glucose (n
= 3) versus those with normal glucose levels (n = 3),
with the most significant CpG site having an adjusted P-
value of 0.85. However, the limited sample size prevents
us from drawing any conclusion based on this analysis.
Unfortunately, fasting glucose was not measured in the
replication cohort. Future studies with large sample sizes
and more detailed phenotypes will be needed to clarify
this question.
Conclusion
In this study, we identified several reproducible changes
in DNA methylation of peripheral blood leukocytes
between obese cases and lean controls. This study pro-
vides evidence that obesity is associated with methyla-
tion changes in blood leukocyte DNA. Further studies
are warranted to determine the causal direction of this
relationship as well as whether such methylation
changes can lead to immune dysfunction. Such studies
will have the ability to identify new insight into disease
etiology and provide new targets for prevention of obe-
sity related diseases such as cardiovascular diseases and
type 2 diabetes.
Additional material
Additional file 1: Primer sequences and PCR conditions for bisulfit-
pyrosequencing analysis.
Additional file 2: Meta-analysis for the six CpG sites.
Additional file 3: Correlations among the multiple CpG sites within
one gene.
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